Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis

被引:5
作者
Lassen, Ulrik [1 ]
Bokemeyer, Carsten [2 ]
Garcia-Foncillas, Jesus [3 ]
Italiano, Antoine [4 ]
Vassal, Gilles [5 ]
Paracha, Noman [6 ]
Marian, Marisca [6 ]
Chen, Yuxian [7 ]
Linsell, Louise [7 ,8 ]
Abrams, Keith [7 ]
机构
[1] Univ Copenhagen, Rigshosp, Copenhagen, Denmark
[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[3] Autonomous Univ, Univ Hosp Fdn Jimenez Diaz, Univ Canc Inst, Dept Oncol, Madrid, Spain
[4] Inst Bergonie, Bordeaux, France
[5] Gustave Roussy Comprehens Canc Ctr, Villejuif, France
[6] Bayer Pharmaceut, Basel, Switzerland
[7] Visible Analyt, Oxford, England
[8] Visible Analyt, 3 Kings Meadow, Oxford OX2 0DP, England
关键词
LAROTRECTINIB; THERAPIES;
D O I
10.1200/PO.22.00651
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSEEvidence suggests that neurotrophic tyrosine receptor kinase (NTRK) gene fusions in solid tumors are predictive biomarkers for targeted inhibition across a number of adult and pediatric tumor types. However, despite robust clinical response to tyrosine receptor kinase (TRK) inhibitors, the natural history and prognostic implications of NTRK fusions in solid tumors are poorly understood. It is important to evaluate their prognostic significance on survival to provide some context to the clinical effectiveness observed in clinical trials of TRK-targeted therapies.METHODSA systematic literature review was conducted in Medline, Embase, Cochrane, and PubMed to identify studies comparing the overall survival (OS) of patients with NTRK fusion-positive (NTRK+) versus NTRK fusion-negative (NTRK-) tumors. Five retrospective matched case-control studies published before 11 August 2022 were assessed for inclusion, and three were selected for the meta-analysis (sample size: 69 NTRK+, 444 NTRK-). Risk of bias was assessed using the Risk of Bias Assessment tool for Non-randomized Studies tool. The pooled hazard ratio (HR) was estimated using a Bayesian random-effects model.RESULTSIn the meta-analysis, the median follow-up ranged from 2 to 14 years and the median OS was between 10.1 and 12.7 months (where reported). Comparing patients with tumors NTRK+ and NTRK-, the pooled HR estimate for OS was 1.51 (95% credible interval, 1.01 to 2.29). The patients analyzed had no previous or current exposure to TRK inhibitors.CONCLUSIONIn patients not treated with TRK inhibitor therapies, those with NTRK+ solid tumors have a 50% increased risk of mortality within 10 years from diagnosis or the start of standard therapy compared with those with NTRK- status. Although this is the most robust estimate of the comparative survival rate to date, further studies are required to reduce uncertainty.
引用
收藏
页数:13
相关论文
共 20 条
[1]   TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting [J].
Bazhenova, Lyudmila ;
Lokker, Andrew ;
Snider, Jeremy ;
Castellanos, Emily ;
Fisher, Virginia ;
Fellous, Marc ;
Nanda, Shivani ;
Zong, Jihong ;
Keating, Karen ;
Jiao, Xiaolong .
TARGETED ONCOLOGY, 2021, 16 (03) :389-399
[2]   Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project [J].
Bridgewater, John ;
Jiao, Xiaolong ;
Parimi, Mounika ;
Flach, Clare ;
Stratford, Jeran ;
Kamburov, Atanas ;
Schmitz, Arndt A. ;
Zong, Jihong ;
Reeves, John A. ;
Keating, Karen ;
Bruno, Amanda ;
Fellous, Marc ;
Pereira, Mariana Buongermino ;
Bazhenova, Lyudmila .
CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 33
[3]  
Bridgewater J, 2021, CANCER RES, V81
[4]   NTRK fusion-positive cancers and TRK inhibitor therapy [J].
Cocco, Emiliano ;
Scaltriti, Maurizio ;
Drilon, Alexander .
NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (12) :731-747
[5]   Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors [J].
Demetri, George D. ;
De Braud, Filippo ;
Drilon, Alexander ;
Siena, Salvatore ;
Patel, Manish R. ;
Cho, Byoung Chul ;
Liu, Stephen, V ;
Ahn, Myung-Ju ;
Chiu, Chao-Hua ;
Lin, Jessica J. ;
Goto, Koichi ;
Lee, Jeeyun ;
Bazhenova, Lyudmila ;
John, Thomas ;
Fakih, Marwan ;
Chawla, Sant P. ;
Dziadziuszko, Rafal ;
Seto, Takashi ;
Heinzmann, Sebastian ;
Pitcher, Bethany ;
Chen, David ;
Wilson, Timothy R. ;
Rolfo, Christian .
CLINICAL CANCER RESEARCH, 2022, 28 (07) :1302-1312
[6]   Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children [J].
Drilon, A. ;
Laetsch, T. W. ;
Kummar, S. ;
DuBois, S. G. ;
Lassen, U. N. ;
Demetri, G. D. ;
Nathenson, M. ;
Doebele, R. C. ;
Farago, A. F. ;
Pappo, A. S. ;
Turpin, B. ;
Dowlati, A. ;
Brose, M. S. ;
Mascarenhas, L. ;
Federman, N. ;
Berlin, J. ;
El-Deiry, W. S. ;
Baik, C. ;
Deeken, J. ;
Boni, V. ;
Nagasubramanian, R. ;
Taylor, M. ;
Rudzinski, E. R. ;
Meric-Bernstam, F. ;
Sohal, D. P. S. ;
Ma, P. C. ;
Raez, L. E. ;
Hechtman, J. F. ;
Benayed, R. ;
Ladanyi, M. ;
Tuch, B. B. ;
Ebata, K. ;
Cruickshank, S. ;
Ku, N. C. ;
Cox, M. C. ;
Hawkins, D. S. ;
Hong, D. S. ;
Hyman, D. M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (08) :731-739
[7]  
European Medicines Agency, 2019, Vitrakvi-EPAR-Medicines overview
[8]   A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors [J].
Forsythe, Anna ;
Zhang, Wei ;
Phillip Strauss, Uwe ;
Fellous, Marc ;
Korei, Maesumeh ;
Keating, Karen .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
[9]   Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves [J].
Guyot, Patricia ;
Ades, A. E. ;
Ouwens, Mario J. N. M. ;
Welton, Nicky J. .
BMC MEDICAL RESEARCH METHODOLOGY, 2012, 12
[10]   Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors [J].
Hibar, Derrek P. ;
Demetri, George D. ;
Peters, Solange ;
Davies, Jessica ;
Humblet, Olivier ;
Maund, Sophia L. ;
Perez, Laura .
PLOS ONE, 2022, 17 (08)